Nama's AI scorecard currently rates PROCEPT BioRobotics Sell (3.2 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.

When does PRCT report earnings?

PROCEPT BioRobotics's next scheduled report is on Feb 25, 2027. Analysts expect EPS of -$0.25.

What is the PRCT price target?

The median analyst price target from 12 analysts is $20.50, with a range of $16.00 – $30.00.

Is PRCT Shariah compliant?

Nama's AAOIFI-style screen reads PROCEPT BioRobotics as Shariah Compliant. Passes our debt, cash and income screen; not a scholar's ruling.

Nama Insights

PROCEPT BioRobotics (PRCT)

Healthcare · Medical Devices · NASDAQ

PROCEPT BioRobotics (PRCT) is a Healthcare company in the Medical Devices industry. It has a market capitalization of $1.19B and a free-cash-flow yield of -5.1%. Over the most recent reported fiscal year, revenue grew 37.2%. Nama's AI scorecard rates it Sell, 3.2 out of 10. On 12-month momentum it ranks in the trailing band of its market.

AI scorecard

Sell · 3.2/10

Negative, at the mild end of Sell. As of Nov 7, 2026.

Momentum

Trailing · -42.8% over 12 months ex. last

Bottom 20% of its market on the past year's move.

Shariah screen

Shariah Compliant

Passes our debt, cash and income screen; not a scholar's ruling.

Off its high

-80.1%

How far the last close sits under the highest price of the past five years.

Market cap	$1.19B
Trailing P/E	—
Price / book	3.5
Price / sales	3.5
FCF yield	-5.1%
Dividend yield	—
Gross margin	64.2%
Operating margin	-33.9%
Net margin	-32.5%
Revenue growth (YoY)	+37.2%
Revenue growth (3-yr annual)	+60.1%
EPS growth (YoY)	—
FCF/share growth (YoY)	—
Beta	0.9
Exchange	NASDAQ
Sector	Healthcare
Industry	Medical Devices

PRCT earnings

Next report: Feb 25, 2027 (Q4 2026, EPS estimate -$0.25). Beat the EPS estimate in 0 of 4 recent quarters.

Quarter	Reported	EPS	Estimate	Surprise	Revenue
Q3 2026	Nov 4, 2026	-$0.46	-$0.39	-17.9%	$98.29M
Q2 2026	Aug 4, 2026	-$0.47	-$0.45	-4.4%	$94.50M
Q1 2026	Apr 29, 2026	-$0.56	-$0.56	+0.0%	$83.13M
Q4 2025	Feb 25, 2026	-$0.53	-$0.32	-65.6%	$76.38M

PRCT analyst price target

Median target $20.50 from 12 analysts, ranging $16.00 – $30.00.

Medical Devices peers

Ticker	Company	Market cap	P/E
ABT	Abbott Laboratories	$190.39B	20.4
MDT	Medtronic	$130.22B	17.8
SYK	Stryker	$124.06B	22.8
BSX	Boston Scientific	$61.96B	13.4
EW	Edwards Lifesciences	$58.73B	34.7
GEHC	GE HealthCare Technologies	$37.25B	16.8
PHG	Koninklijke Philips	$29.67B	15.2
DXCM	DexCom	$29.62B	29.7

Explore live PRCT data on Nama Insights →

PRCT FAQ

Is PRCT a buy?: Nama's AI scorecard currently rates PROCEPT BioRobotics Sell (3.2 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.
When does PRCT report earnings?: PROCEPT BioRobotics's next scheduled report is on Feb 25, 2027. Analysts expect EPS of -$0.25.
What is the PRCT price target?: The median analyst price target from 12 analysts is $20.50, with a range of $16.00 – $30.00.
Is PRCT Shariah compliant?: Nama's AAOIFI-style screen reads PROCEPT BioRobotics as Shariah Compliant. Passes our debt, cash and income screen; not a scholar's ruling.